Shomit Sengupta brings over 10 years of drug discovery experience focused on metabolism and related signaling pathways to Atavistik Bio. He is an accomplished scientist and manager with a strong publication record and experience in both early and late-stage drug development. Most recently, Shomit was an Associate Director at Agios Pharmaceuticals, where he managed teams of scientists responsible for validating new therapeutic targets and evaluating new indications for existing assets for the rare genetic disease portfolio. He joined Agios from Navitor Pharmaceuticals where he was the lead biologist from discovery to IND for a first-in-class modulator of leucine sensing for treatment-resistant depression. Prior to Navitor, Shomit worked on cell pharmacology screening efforts at the Center for the Development of Therapeutics at the Broad Institute, and the development and execution of clinical biomarker assays at Catabasis Pharmaceuticals.
Shomit received his PhD in Biology from the Whitehead Institute at MIT and did his postdoctoral training in the lab of Joan Brugge at Harvard Medical School.